1. A systematic review of basket and umbrella trials in oncology: the importance of tissue of origin and molecular target. (January 2023) Authors: Haslam, Alyson; Olivier, Timothée; Tuia, Jordan; Prasad, Vinay Journal: European journal of cancer Issue: Volume 178(2023) Page Start: 227 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Crossover in Adjuvant Trastuzumab Trials: Sparing Toxicity in Patient Care. (8th September 2022) Authors: Tuia, Jordan E.; Olivier, Timothée; Prasad, Vinay K. Journal: American journal of clinical oncology Issue: Volume 45:Number 10(2022) Page Start: 438 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Dose modification rules and availability of growth factor support: A cross-sectional study of head-to-head cancer trials used for US FDA approval from 2009 to 2021. (September 2022) Authors: Olivier, Timothée; Haslam, Alyson; Prasad, Vinay Journal: European journal of cancer Issue: Volume 172(2022) Page Start: 349 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Estimation of time cost of anti-cancer drugs approved based on comparisons to best supportive care: A cross sectional analysis. (December 2022) Authors: Prasad, Vinay; Olivier, Timothée; Chen, Emerson Y.; Haslam, Alyson Journal: Journal of cancer policy Issue: Volume 34(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Eventual success rate and predictors of success for oncology drugs tested in phase I trials. Issue 2 (5th July 2022) Authors: Haslam, Alyson; Olivier, Timothée; Powell, Kerrington; Tuia, Jordan; Prasad, Vinay Journal: International journal of cancer Issue: Volume 152:Issue 2(2023) Page Start: 276 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. FDA precedents in drug approvals: Contradiction in promoting more treatment options. (July 2022) Authors: Olivier, Timothée; Prasad, Vinay Journal: European journal of cancer Issue: Volume 169(2022) Page Start: 123 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Frontline Dual Checkpoint Inhibition in Metastatic Melanoma Over Anti–PD-1 Monotherapy: The Case for a Comparative Randomized Controlled Trial. Issue 14 (10th May 2022) Authors: Olivier, Timothée; Prasad, Vinay Journal: Journal of clinical oncology Issue: Volume 40:Issue 14(2022) Page Start: 1596 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review. (March 2021) Authors: Thouvenin, Laure; Olivier, Timothée; Banna, Giuseppe; Addeo, Alfredo; Friedlaender, Alex Journal: Therapeutic advances in drug safety Issue: Volume 12(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?. (June 2021) Authors: Olivier, Timothée; Fernandez, Eugenio; Labidi-Galy, Intidhar; Dietrich, Pierre-Yves; Rodriguez-Bravo, Veronica; Baciarello, Giulia; Fizazi, Karim; Patrikidou, Anna Journal: Cancer treatment reviews Issue: Volume 97(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. The iceberg plot, improving the visualisation of therapy response in oncology in the era of sequence-directed therapy. (December 2021) Authors: Lythgoe, Mark P.; Olivier, Timothée; Prasad, Vinay Journal: European journal of cancer Issue: Volume 159(2021) Page Start: 56 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗